(VIANEWS) – SCATEC (SCATC.OL), NEOEN (NEOEN.PA), PERNOD RICARD (RI.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SCATEC (SCATC.OL)
121.2% sales growth and 11.65% return on equity
Scatec ASA, together with its subsidiaries, provides renewable energy solutions worldwide. The company operates through Power Production; Services; and Development & Construction segments. It produces and sells solar, winds, and hydro generated electricity. The company also develops, builds, owns, and operates solar, wind, and hydro power plants and storage solutions. The company is also involved in the engineering, procurement, and construction, as well as operation, maintenance, and asset management of power plants. It has a total of 4.2 GW in operation and under construction. The company was formerly known as Scatec Solar ASA and changed its name to Scatec ASA in November 2020. Scatec ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, SCATEC has a trailing twelve months EPS of kr2.01.
PE Ratio
SCATEC has a trailing twelve months price to earnings ratio of 38.76. Meaning, the purchaser of the share is investing kr38.76 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.65%.
Sales Growth
SCATEC’s sales growth is negative 4.8% for the present quarter and 121.2% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 19, 2023, the estimated forward annual dividend rate is 1.94 and the estimated forward annual dividend yield is 2.78%.
More news about SCATEC.
2. NEOEN (NEOEN.PA)
48.5% sales growth and 3.27% return on equity
Neoen S.A., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. The company operates through Solar Power, Wind Power, Storage, Farm-Down, Development and Investments, and Eliminations segments. It operates in Argentina, Australia, Canada, Ecuador, the United States, Finland, France, Ireland, Italy, Jamaica, Mexico, Mozambique, Portugal, El Salvador, Sweden, and Zambia. Neoen S.A. was incorporated in 2008 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NEOEN has a trailing twelve months EPS of €0.94.
PE Ratio
NEOEN has a trailing twelve months price to earnings ratio of 27.91. Meaning, the purchaser of the share is investing €27.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.27%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 20, 2024, the estimated forward annual dividend rate is 0.15 and the estimated forward annual dividend yield is 0.39%.
Yearly Top and Bottom Value
NEOEN’s stock is valued at €26.24 at 22:20 EST, way under its 52-week high of €38.56 and way higher than its 52-week low of €21.80.
Volume
Today’s last reported volume for NEOEN is 300989 which is 88.61% above its average volume of 159578.
More news about NEOEN.
3. PERNOD RICARD (RI.PA)
7.9% sales growth and 12.18% return on equity
Pernod Ricard SA produces and sells wines and spirits worldwide. The company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 Pipers, Aberlour, Absolut, Absolut Elyx, Altos, ARARAT, Augier, Avion, Ballantine's, Becherovka, Beefeater, Blenders Pride, Brancott Estate, Campo Viejo, Ceder's, Chivas, Church Road, Clan Campbell, Del Maguey, George Wyndham, Green Spot, Havana Club, Imperial, Imperial Blue, Italicus, J.P. Wiser's, Jacob's Creek, Jameson, Jefferson's, Kahlúa, Kenwood, KI NO BI, Lillet, Long John, L'Orbe, Lot No. 40, Malfy, Malibu, Martell, Method & Madness, Midleton Very Rare, Minttu, Monkey 47, Mumm, Olmeca, Ostoya, Passport Scotch, Pastis 51, Pernod, Perrier-Jouët, Plymouth Gin, Powers, Rabbit Hole, Ramazzotti, Redbreast, Ricard, Royal Salute, Royal Stag, Scapa, Seagram's Gin, Secret Speyside, Smooth Ambler, Something Special, St Hugo, Stoneleigh, Suze, The Glenlivet, TX, Wyborowa, and Ysios. It also provides non-alcoholic beverages under the brands Ceder's, Suze Tonic 0%, Cinzano Spritz 0%, Pacific, Campo Viejo Sparkling 0%, and Jacob's Creek Unvined. Pernod Ricard SA was founded in 1805 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, PERNOD RICARD has a trailing twelve months EPS of €8.04.
PE Ratio
PERNOD RICARD has a trailing twelve months price to earnings ratio of 18.65. Meaning, the purchaser of the share is investing €18.65 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.18%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 7.4%, now sitting on 11.61B for the twelve trailing months.
More news about PERNOD RICARD.
4. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Sales Growth
SANOFI’s sales growth for the next quarter is 7.4%.
Volume
Today’s last reported volume for SANOFI is 1839940 which is 37.38% above its average volume of 1339290.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 47.08B for the twelve trailing months.
More news about SANOFI.
5. DASSAULT SYSTEMES (DSY.PA)
6.9% sales growth and 14.34% return on equity
Dassault Systèmes SE provides software solutions and services worldwide. It offers SOLIDWORKS provides easy-to-use 2D and 3D product development solutions accessible to any business; CATIA, an engineering and design software for product 3D computer-aided design; GEOVIA for intersection of natural resources, infrastructure, and urban planning; and BIOVIA that develops chemicals, biologics, and materials experiences. The company provides SIMULIA that delivers realistic simulation applications; DELMIA, which enables global industrial operations; 3DVIA that provides 3D space planning solutions; and ENOVIA that enables to plan and track the definition of success for customer. In addition, it offers Centric PLM, a product lifecycle management software solution; 3DEXCITE, a real-time 3D visualization software; NETVIBES, which enables organizations to gather, align, and enrich big data; 3DEXPERIENCE platform that provides organizations a holistic and real-time view of their business activities and ecosystem, as well as connecting people, ideas, data, and solutions together in a single environment; and MEDIDATA, a clinical research study software that provides evidences and insights to pharmaceutical, biotech, medical device, and diagnostic companies, as well as academic researchers. The company distributes its products through direct and indirect sales channels. It primarily serves companies in the transportation and mobility; industrial equipment; aerospace and defense; high-tech; life sciences and healthcare; infrastructure, energy, and materials; home and lifestyle; architecture, engineering, and construction; cities, and public services; consumer packaged goods and retail; marine and offshore; and business services. Dassault Systèmes SE was incorporated in 1981 and is headquartered in Vélizy-Villacoublay, France.
Earnings Per Share
As for profitability, DASSAULT SYSTEMES has a trailing twelve months EPS of €0.79.
PE Ratio
DASSAULT SYSTEMES has a trailing twelve months price to earnings ratio of 51.95. Meaning, the purchaser of the share is investing €51.95 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.34%.
Yearly Top and Bottom Value
DASSAULT SYSTEMES’s stock is valued at €41.04 at 22:20 EST, way below its 52-week high of €48.88 and way higher than its 52-week low of €32.25.
Sales Growth
DASSAULT SYSTEMES’s sales growth for the next quarter is 6.9%.
Volume
Today’s last reported volume for DASSAULT SYSTEMES is 1539720 which is 22.94% above its average volume of 1252340.
Moving Average
DASSAULT SYSTEMES’s value is way above its 50-day moving average of €34.61 and higher than its 200-day moving average of €39.99.
More news about DASSAULT SYSTEMES.
